Targets › IL7R
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout May 2028.
Receptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP). (UniProt, P16871)
Open in Phaseline: the race on IL7R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Allterum Therapeutics | 4A10 (Molecule B4532) Anti-CD127 (IL-7Rα) monoclonal antibody | IL7R | Phase 1 | Lymphoblastic Lymphoma | May 2028 |
| Chulalongkorn University | CMD63 CD19-targeted CAR-T cell with IL-7Rα signaling domain | CD19, IL7R | Phase 1 | Relapse B Acute Lymphoblastic Leukemia | Sep 2028 |
Lymphoblastic Lymphoma (1) Relapse B Acute Lymphoblastic Leukemia (1)
small molecule (1), other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.